rHEALTH Targets $323 Billion Diagnostics Market with NASA-Tested At-Home Tech

rHEALTH is positioning itself to disrupt the global blood diagnostics industry with a portable, lab-quality testing device designed for home and point-of-care use. The system aims to provide rapid results from self-collected blood samples, reducing the time to interpret results from weeks to under 20 minutes. Originally developed to monitor astronaut health on the International Space Station, the technology addresses a critical gap in global healthcare. The World Health Organization estimates that 4.5 billion people lack timely access to diagnostic testing, which often leads to significant delays in treating chronic conditions for millions of adults. The rHEALTH ONE platform is designed to support more than 100 different tests and is protected by 17 U.S. patents covering its architecture and algorithms. The company has secured over $20 million in non-dilutive funding and has established strategic collaborations with major institutions, including the Mayo Clinic, AstraZeneca, and the National Institutes of Health (NIH). Operating within a $323 billion global diagnostics and patient monitoring market, rHEALTH plans to generate revenue through a combination of hardware sales, disposable test cartridges, and software subscriptions. The company is currently targeting FDA registration within the next 12 months to transition its space-tested prototypes into commercial healthcare settings.